Adamis pharmaceuticals provides update on its us compounding business

San diego, jan. 26, 2021 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp) today announced that it has entered into a non-binding letter of intent with a potential buyer for sale of substantially all of the assets of its us compounding inc. (usc) subsidiary. under the terms described in the letter of intent, the buyer would agree to acquire substantially all of the assets of us compounding in exchange for a total gross consideration that could range from approximately $10-20 million, before transaction fees and expenses and other potential post-closing adjustments.
ADMP Ratings Summary
ADMP Quant Ranking